Moximed, Inc. announced today that the KineSpring® System, an implantable medical spring that works by unloading the weight on the diseased knee joint, has been successfully implanted in the first patient enrolled in its US clinical study, SOAR.
This prospective, single-arm clinical study of the KineSpring System in patients with medial compartment knee osteoarthritis will enroll a total of 30 patients at six leading orthopaedic centers across the United States. The study's Lead Principal Investigator is Jack Farr, M.D., Director of the OrthoIndy Cartilage Restoration Center of Indiana and the OrthoIndy Sports Medicine Fellowship Program. The objectives of the study are to evaluate the safety and effectiveness of the KineSpring System for the treatment of knee OA in a US patient group.
"Previous clinical experience with the KineSpring System in Europe and Australia has shown favorable results," noted Principal Investigator Dennis C. Crawford, M.D., Ph.D., Associate Professor of Orthopedic Surgery and Director of Sports Medicine at Oregon Health & Science University in Portland, Oregon, who performed the first procedure in the United States in December 2012. "My Co-investigators and I are encouraged by this experience and believe the KineSpring System could prove to be an effective treatment option in active individuals, with early knee osteoarthritis, who are interested in a procedure that is less invasive than joint replacement surgery."
"The start of the SOAR clinical trial with the KineSpring System is a significant milestone for Moximed. The KineSpring System is already commercialized in the major European markets, and we look forward to seeing the results and progressing with the product's development in the US," noted Kevin Sidow, President and CEO of Moximed.
Clinical trial shows MRI and tracking-guided delivery of magnetic stimulation to brains of people with severe depression eases symptoms